3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 1
2
Phase NA
1
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Gastrointestinal
3
Sarcoma
2
Thoracic
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Breast
1
Conditions
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Cisplatin
5
lenvatinib
4
Fentanyl
4
Morphine
3
Fluorouracil
3
Docetaxel
3
trametinib
2
selpercatinib
2
pralsetinib
2
pembrolizumab
2
nimotuzumab
2
larotrectinib
2
dabrafenib
2
cabozantinib
2
anlotinib
2
Thyrotropin Alfa
2
Saline Solution
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Norepinephrine
2
Metformin
2
Indocyanine Green
2
Gabapentin
2
Cinacalcet
2
Cetuximab
2
Carboplatin
2
Benzydamine
2
Acetaminophen
2
xiaojin wan
1
vandetanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Sunitinib
×
Head & Neck
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled